ESR1 and breast carcinoma: The axillary response to NST is subtype-dependent and patients with human epidermal growth factor receptor 2 positive (HER2-positive) and triple negative (TN) breast cancer are more likely to achieve axillary pathologic complete response (axillary pCR) than patients with estrogen receptor (ER)-positive breast cancer [4].